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OBJECTIVES: To evaluate whether infliximab, a modern off-label biologic, is cost-
effective for treating sarcoid posterior uveitis compared to methotrexate and sys-
temtic steroids. Sarcoid posterior uveitis is a progressive eye disease that can lead
to blindness if untreated. Ophthalmologists have utilized infliximab, a TNF-alpha
inhibitor, which reverses effects of uveitis. METHODS: A semi-Markov model fol-
lowed patients’ therapy from the onset of sarcoid posterior uveitis using the soci-
etal perspective. The lifetime model simulated health states that could lead to
successful reversal of uveitis with standard or intensified treatment with systemic
steroids, methotrexate, or infliximab. Probabilities, health utilities, and costs were
included in the model based on findings from literature. Costs and effects were
discounted at 3% ($US; 2010 values). We conducted univariate sensitivity analyses,
threshold analyses, and a Bayesian multivariate probablistic sensitivity analysis
using 10,000 Monte Carlo simulations. Results were interpretted from a predeter-
mined willingness-to-pay of $50,000/QALY. RESULTS: In order of cost, base case
results showed systemic steroids most affordable ($26,871; 14.58 QALYs), followed
by methotrexate ($40,351; 15.92 QALYs), and then infliximab ($46,547; 15.04
QALYs). Methotrexate was cost-effective compared to steroids, with an incremen-
tal cost-effectiveness ratio of $10,053/QALY. Methotrexate dominated infliximab.
Univariate sensitivity analyses suggested that the model was sensitive to the utility
of a patient’s successful recovery from uveitis (0.84 QALYs). If patients’ health
utility after successful recovery is below 0.750, then infliximab has a greater net
benefit than methotrexate. The multivariate probabilistic sensitivity analysis
showed that methotrexate dominated infliximab in 60% of the simulations.
CONCLUSIONS: This cost-effectiveness analysis suggests that despite major ad-
vances in the use of biologics for treating sight-threatening sarcoid posterior uve-
itis, methotrexate remains a less expensive and more cost-effective strategy. Meth-
otrexate should be adopted as the standard of care for treatment considering its
incremental cost-effectiveness at a reasonable willingness-to-pay. Other thera-
peutic options, such as infliximab, may be considered for certain cases.
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OBJECTIVES: Pharmacoeconomic analyses (PEs) were performed in five European
countries to determine costs, consequences and cost effectiveness of a partially
hydrolysed 100% whey-based infant formula, manufactured by Nestlé S.A, Swit-
zerland (PHF-W) in the prevention of atopic dermatitis (AD) in ‘at risk’ children
when compared to standard cow’s milk formula (SF) or extensively hydrolyzed
formula (EHF). METHODS: The PEs were performed in France, Germany, Spain,
Denmark and Switzerland, using decision-analytic models depicting AD treatment
pathways, as well as resource utilisation and costs associated with the treatment of
AD in healthy yet ‘at risk’ newborns who could not be exclusively breastfed. A time
horizon of 12 months including 6 months of formula consumption was applied,
with country-specific resource use and costs. In four settings, SF was the main
comparator and the final outcome of the PEs was the incremental cost per avoided
case (ICER) of AD when comparing subjects who used PHF-W versus SF. Given a lack
in significant differences in efficacy between PHF-W and EHF, a cost-minimization
approach was used in all settings to compare these formulas. Three perspectives
were applied: the Ministry of Health (MOH), the family and society. RESULTS: The
analyses of PHF-W vs. SF generated ICERs ranging from €801 to €1343 (MOH), from
-€1796 to -€454 (family) and from -€995 to €719 (society). The costs of formula and
time loss were the most important cost drivers. In the analyses of PHF-W versus
EHF in prevention, PHF-W demonstrated savings ranging from €4-€120 million, or
€1.3-€64 million for the MOH perspective. The robustness of the models and the
direction of the results were confirmed by one-way and probabilistic sensitivity
analyses. CONCLUSIONS: In five European countries, PHF-W appears to be the
product best positioned in prevention at a reasonable cost when compared to SF
and with important cost-savings versus EHF.
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OBJECTIVES: To evaluate cost-effectiveness of ustekinumab vs etanercept for se-
vere psoriasis in Russia. METHODS: Cost-effectiveness analysis was performed.
The data about efficacy and safety of biologic agents was analyzed. Cost-effective-
ness ratio (CER) was calculated for ustekinumab and etanercept. Pharmaceutical
costs were taken into account only. Achievement of PASI 75 was a criterion of
efficacy, data about it was extracted from 12 weeks comparative clinical trial.
RESULTS: The efficacy of ustekinumab was higher than etanercept in a direct
comparative trial (67.5 and 56.8% of patients achieved PASI 75 by week 12 respec-
tively). Both biologic agents were generally well tolerated in most patients. Usteki-
numab was a bit less costly than etanercept: 470.00 and 496.62 thousands rub (16.92
and 17.88 thousands $) for 12-weeks treatment respectively. Therefore CER was
more favorable for ustekinumab than for etanercept: 696.30 thousands rub (25.06
thousands $) and 874.33 thousands rub ($31.47 thousands $) per patient with PASI
75 achieved respectively. CONCLUSIONS: Ustekinumab is a dominanting alterna-
tive to etanercept for patients with severe psoriasis in Russia.
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OBJECTIVES: Ozurdex (dexamethasone 700 g intravitreal implant in applicator)
was the first EMA licensed pharmacotherapy for macular oedema following central
and branch retinal vein occlusion (CRVO, BRVO), a leading cause of vision loss. The
objective of this analysis was to evaluate the cost-effectiveness of Ozurdex com-
pared with a strategy of observation for the treatment of macular oedema (ME)
following CRVO, and for BRVO patients with macular haemorrhage (BRVO-MH) or
who have failed prior laser treatment (BRVO-PL). The analysis was performed from
a UK NHS perspective. METHODS: A cost-utility model was developed to estimate
the lifetime costs and effects of Ozurdex compared with observation in patients
with CRVO, BRVO-MH and BRVO-PL based on the GENEVA 008 and GENEVA 009
studies. Patients in the model could move between six BCVA defined health states
(best corrected visual acuity) based on the number of letters read correctly on the
Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Cost data were ob-
tained from literature and NHS reference costs. Utility values ranged between 0.599
and 0.862 and were derived from a preference-based scoring algorithm, the Visual
Function Questionnaire Utility Index (VFQ-UI), valued by members of the general
population using time-trade off (TTO). RESULTS: Ozurdex was shown to be cost-
effective relative to observation with ICERs of £16,522, £17,741 and £6,361 for pa-
tients with CRVO, BRVO-MH and BRVO-PL respectively. One-way sensitivity anal-
ysis demonstrated that the proportion of patients affected in the baseline defined
worse-seeing eye was a key driver of cost-effectiveness. Probabilistic sensitivity
analysis demonstrated that at a threshold of £30,000, Ozurdex was a cost effective
option in 85.2% of simulations for CRVO, 82.1% of simulations for BRVO-MH and
98.2% of simulations for BRVO-PL.CONCLUSIONS:Ozurdex is a cost-effective treat-
ment option from a UK NHS perspective for macular oedema secondary to CRVO,
BRVO-MH and BRVO-PL.
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OBJECTIVES: Ozurdex (dexamethasone 700 g intravitreal implant in applicator)
was the first licensed pharmacotherapy for macular oedema following branch ret-
inal vein occlusion (BRVO) in the UK; however unlicenced use of Bevacizumab
given by intravitreal injection was considered a potential comparator for economic
evaluation. No head to head RCTs exist to compare outcomes; a mixed treatment
comparison (MTC) was performed to synthesise available data. METHODS: A life-
time cost-utility model was produced with a treatment period of up to 3 years.
Patients received an average of 9.96 bevacizumab or 2.24 Ozurdex treatments, 75%
of which were costed based on a day case setting. Efficacy was measured in terms
of letters gained on the Early Treatment of Diabetic Retinopathy Study (ETDRS)
chart. This was estimated from an MTC where the network of evidence included
comparisons of Ozurdex versus observation, observation versus grid laser and grid
laser versus bevacizumab. QALYs were calculated from the letters gained using a
coefficient obtained from regression analysis predicting the Visual Function Ques-
tionnaire Utility Index (VFQ-UI) score from BCVA. Differences in AE profiles were
accounted for within the analysis. RESULTS: The day 180 results of the MTC indi-
cated a difference (pns) in BCVA of 1.74 letters (95% CI -9.57 to 6.19) favouring
bevacizumab; MTC Results at day 60 show this trend to be reversed. The analysis
also demonstrated that an Ozurdex based regimen is less costly than a bevaci-
zumab regimen making the ICER difficult to interpret. Therefore net monetary
benefit (NMB) was calculated to demonstrate an NMB of Ozurdex vs. bevacizumab
(based on day 180 results) of £2,228 at a willingness to pay per QALY of £20,000,
robust to sensitivity analyses. CONCLUSIONS: The results of this analysis indicate
that Ozurdex is a cost-effective treatment for macular oedema following BRVO
when compared with bevacizumab, from a UK NHS perspective.
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OBJECTIVES: Cost-effectiveness models in age-related macular degeneration use
the utilities based on the better-seeing eye, because this mainly influence quality of
life. Most models use the utility as if we only treat better-seeing eyes, although in
trials the majority of the treated eyes are the poorer-seeing eyes. This discrepancy
results in overestimating the QALY. Therefore a correction should be applied. The
objective of this study is to estimate the influence on the (incremental) cost-effec-
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